Mega Genomics Limited (HKG:6667)
Hong Kong
· Delayed Price · Currency is HKD 7.31
+0.32 (4.58%)
Mar 9, 2026, 3:57 PM HKT
Mega Genomics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 138.22 | 164.23 | 151.3 | 145.73 | 237.19 | 203.22 | Upgrade
|
| Revenue Growth (YoY) | -13.46% | 8.54% | 3.82% | -38.56% | 16.71% | 64.28% | Upgrade
|
| Cost of Revenue | 28.35 | 44.88 | 63 | 64 | 70.51 | 56.98 | Upgrade
|
| Gross Profit | 109.87 | 119.35 | 88.3 | 81.72 | 166.68 | 146.24 | Upgrade
|
| Selling, General & Admin | 56.75 | 59.46 | 52.83 | 77.79 | 45.95 | 35.4 | Upgrade
|
| Research & Development | 19.17 | 19.17 | 22.38 | - | - | - | Upgrade
|
| Other Operating Expenses | 0.88 | 0.52 | 0.35 | 2.48 | 5.87 | 3.8 | Upgrade
|
| Operating Expenses | 72.83 | 71.23 | 61.58 | 106.13 | 57.98 | 38.47 | Upgrade
|
| Operating Income | 37.04 | 48.12 | 26.71 | -24.4 | 108.69 | 107.77 | Upgrade
|
| Interest Expense | -1.31 | -1.72 | -1.12 | -0.72 | -6.91 | -16.55 | Upgrade
|
| Interest & Investment Income | 7.34 | 6.08 | 6.07 | 4.01 | 2.98 | 0.34 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.74 | -0.75 | 1.44 | 11.75 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.4 | 0.1 | 3.51 | -12.06 | -8.94 | 3.24 | Upgrade
|
| EBT Excluding Unusual Items | 41.93 | 51.83 | 36.61 | -21.42 | 95.82 | 94.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.2 | 1.2 | -0.43 | - | 0.06 | 0.1 | Upgrade
|
| Other Unusual Items | 0.61 | 0.61 | - | - | - | - | Upgrade
|
| Pretax Income | 43.73 | 53.63 | 36.18 | -21.42 | 95.88 | 94.9 | Upgrade
|
| Income Tax Expense | 8.4 | 8.59 | 6.14 | -3.8 | 16.87 | 15.81 | Upgrade
|
| Net Income | 35.34 | 45.05 | 30.04 | -17.62 | 79.02 | 79.1 | Upgrade
|
| Net Income to Common | 35.34 | 45.05 | 30.04 | -17.62 | 79.02 | 79.1 | Upgrade
|
| Net Income Growth | 10.81% | 49.96% | - | - | -0.10% | 166.40% | Upgrade
|
| Shares Outstanding (Basic) | 205 | 207 | 212 | 206 | 127 | - | Upgrade
|
| Shares Outstanding (Diluted) | 205 | 207 | 212 | 206 | 127 | - | Upgrade
|
| Shares Change (YoY) | -0.61% | -2.05% | 2.65% | 62.09% | - | - | Upgrade
|
| EPS (Basic) | 0.17 | 0.22 | 0.14 | -0.09 | 0.62 | - | Upgrade
|
| EPS (Diluted) | 0.17 | 0.22 | 0.14 | -0.09 | 0.62 | - | Upgrade
|
| EPS Growth | 6.91% | 53.11% | - | - | - | - | Upgrade
|
| Free Cash Flow | 40.64 | 56.39 | 127.83 | -11.92 | 26.47 | 101.79 | Upgrade
|
| Free Cash Flow Per Share | 0.20 | 0.27 | 0.60 | -0.06 | 0.21 | - | Upgrade
|
| Gross Margin | 79.49% | 72.67% | 58.36% | 56.08% | 70.27% | 71.96% | Upgrade
|
| Operating Margin | 26.80% | 29.30% | 17.66% | -16.75% | 45.83% | 53.03% | Upgrade
|
| Profit Margin | 25.57% | 27.43% | 19.85% | -12.09% | 33.31% | 38.92% | Upgrade
|
| Free Cash Flow Margin | 29.40% | 34.34% | 84.49% | -8.18% | 11.16% | 50.09% | Upgrade
|
| EBITDA | 46.95 | 57.24 | 34.97 | -16.08 | 117.05 | 116.31 | Upgrade
|
| EBITDA Margin | 33.97% | 34.85% | 23.11% | -11.03% | 49.35% | 57.23% | Upgrade
|
| D&A For EBITDA | 9.91 | 9.12 | 8.26 | 8.33 | 8.36 | 8.53 | Upgrade
|
| EBIT | 37.04 | 48.12 | 26.71 | -24.4 | 108.69 | 107.77 | Upgrade
|
| EBIT Margin | 26.80% | 29.30% | 17.66% | -16.75% | 45.83% | 53.03% | Upgrade
|
| Effective Tax Rate | 19.20% | 16.01% | 16.97% | - | 17.59% | 16.66% | Upgrade
|
| Advertising Expenses | - | - | - | - | - | 14.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.